Drug Profile

Research programme: TNF-alpha inhibitors - Borean Pharma

Alternative Names: C-type lectin domain-derived TNF antagonist; CTLD-derived trimeric TNF antagonist; DC001-c; DC001-e

Latest Information Update: 03 Dec 2010

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

09 Dec 2005 Borean Pharma has established proof of concept with their TNF-α antagonist for rheumatoid arthritis
16 Aug 2005 This programme is still in active development - (BIO-2005)
23 Feb 2004 Borean Pharma's TNF-α antagonists programme is available for licensing (http://www.boreanpharma.com)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com